United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 20 ug - combivent respimat is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (copd) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. combivent respimat is contraindicated in the following conditions [see warnings and precautions (5.6) ]: - hypersensitivity to any of the ingredients in combivent respimat - hypersensitivity to atropine or any of its derivatives risk summary there are no randomized clinical studies of combivent respimat, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . published literature, including cohort studies, case control studies and case series, over s

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - ipratropium bromide monohydrate 21ug; salbutamol sulfate 120ug - aerosol inhaler, metered dose - 120µg/21µg per dose - active: ipratropium bromide monohydrate 21ug salbutamol sulfate 120ug excipient: dichlorodifluoromethane lecithin trichlorofluoromethane

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - ipratropium bromide monohydrate, salbutamol sulfate - nebuliser solution - 0.5/2.5 mg/mg - adrenergics in combination with anticholinergics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - ipratropium bromide; salbutamol sulfate - nebuliser liquid - 200microgram/1ml ; 1mg/1ml

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - ipratropium bromide (ipratropium bromide monohydrate); salbutamol (salbutamol sulfate) - solution - 0.5mg; 2.5mg - ipratropium bromide (ipratropium bromide monohydrate) 0.5mg; salbutamol (salbutamol sulfate) 2.5mg - antimuscarinics antispasmodics

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - ipratropium bromide monohydrate 0.52mg/2.5ml eqv. to ipratropium bromide anhydrous; salbutamol sulphate 3.01mg/2.5ml eqv. to salbutamol - solution - 0.5 mg/2.5 ml - ipratropium bromide monohydrate 0.52mg/2.5ml eqv. to ipratropium bromide anhydrous 0.5 mg/2.5 ml; salbutamol sulphate 3.01mg/2.5ml eqv. to salbutamol 2.500 mg/2.5 ml

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - ipratropium bromide (ipratropium bromide monohydrate); salbutamol (salbutamol sulfate) - solution - 20mcg; 100mcg - ipratropium bromide (ipratropium bromide monohydrate) 20mcg; salbutamol (salbutamol sulfate) 100mcg - antimuscarinics antispasmodics

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - ipratropium bromide/salbutamol - unknown - 20/100 mcg/acutuation

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - ipratropium bromide/salbutamol - unknown - 20/100 mcg/acutuation

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

boehringer ingelheim (malaysia) sdn. bhd. - salbutamol sulphate; ipratropium bromide monohydrate -